Filtered By:
Cancer: Glioma
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 625 results found since Jan 2013.
Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells
This study aimed to understand the potential role and molecular mechanism of the combination therapy of B7H6-siRNA and temozolomide in glioblastoma cancer. U87 cells were treated with B7H6-siRNA and temozolomide, separately and in combination. Cell viability, stemness, cell migration, and apoptosis were measured. The results of this work presented the synergistic effect of B7H6-siRNA and temozolomide in inhibiting the cancerous features of the U87 cell line. Down-regulating B7H6-siRNA expression inhibited the cell viability of U87 glioblastoma cancer cells and increased their sensitivity to temozolomide. In addition, a not...
Source: Experimental Cell Research - May 29, 2023 Category: Cytology Authors: Nadia Allahyarzadeh Khiabani Mohammad Amin Doustvandi Fateme Mohammadnejad Elnaz Salmani Hassan Kohal Neda Boushehri Mahdi Jafarlou Behzad Baradaran Source Type: research
TAX1BP1 contributes to deoxypodophyllotoxin-induced glioma cell parthanatos via inducing nuclear translocation of AIF by activation of mitochondrial respiratory chain complex I
In this study we explored the downstream signal of activated PARP1 to induce nuclear translocation of AIF in DPT-triggered glioma cell parthanatos. We showed that treatment with DPT (450 nM) induced PARP1 over-activation and Tax1 binding protein 1 (TAX1BP1) distribution to mitochondria in human U87, U251 and U118 glioma cells. PARP1 activation promoted TAX1BP1 distribution to mitochondria by depleting nicotinamide adenine dinucleotide (NAD+). Knockdown of TAX1BP1 with siRNA not only inhibited TAX1BP1 accumulation in mitochondria, but also alleviated nuclear translocation of AIF and glioma cell death. We demonstrated that T...
Source: Acta Pharmacologica Sinica - May 15, 2023 Category: Drugs & Pharmacology Authors: Xuan-Zhong Wang Shi-Peng Liang Xi Chen Zhen-Chuan Wang Chen Li Chun-Sheng Feng Shan Lu Chuan He Yu-Bo Wang Guang-Fan Chi Peng-Fei Ge Source Type: research
GSE222571 Haploinsufficiency of NFKBIA reshapes the epigenome and imparts disease fate in diffuse gliomas
Contributors : Markus Bredel ; Llu ís Espinosa ; Teresa Lobo-JarneSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensThis dataset used H3K27me3 ChIP-seq profiling of normal immortalized human astrocytes that are wild-type or have been genetically modified to by CRISPR to knockout NFKBIA or by siRNA to mimic a hemizygous NFKBIA loss
Source: GEO: Gene Expression Omnibus - April 28, 2023 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research
A novel prognostic related lncRNA signature associated with amino acid metabolism in glioma
ConclusionNovel amino-related lncRNAs associated with the survival of glioma patients were identified, and a lncRNA signature can predict glioma prognosis and therapy response, which possibly has vital roles in glioma. Meanwhile, it emphasized the importance of amino acid metabolism in glioma, particularly in providing deeper research at the molecular level.
Source: Frontiers in Immunology - April 11, 2023 Category: Allergy & Immunology Source Type: research
Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior
Oncotarget. 2023 Mar 21;14:219-235. doi: 10.18632/oncotarget.28388.ABSTRACTGlypicans (GPC1-6) are associated with tumorigenic processes and their involvement in neoplastic behavior has been discussed in different cancer types. Here, a cancer-wide GPC expression study, using clinical cancer patient data in The Cancer Genome Atlas, reveals net upregulation of GPC1 and GPC2 in primary solid tumors, whereas GPC3, GPC5 and GPC6 display lowered expression pattern compared to normal tissues. Focusing on GPC1, survival analyses of the clinical cancer patient data reveal statistically significant correlation between high expression...
Source: Oncotarget - March 21, 2023 Category: Cancer & Oncology Authors: Fang Cheng Victor Ch érouvrier Hansson Grigorios Georgolopoulos Katrin Mani Source Type: research
LncRNA PANTR1 is Associated with Poor Prognostic and Suppresses Apoptosis in Glioma
In conclusion, this study provides the first evidence that PANTR1 has a relevant role in human glioma by influencing cell viability and cell death.PMID:36861062 | PMC:PMC9970703 | DOI:10.1155/2023/8537036
Source: Journal of Oncology - March 2, 2023 Category: Cancer & Oncology Authors: Fei Shi Jie Hu Ping Zheng Yisong Lv Hongyu Liu Guiyun Zhang Hongyu Jiang Source Type: research
The prognostic value of DAAM2 in lower grade glioma, liver cancer, and breast cancer
CONCLUSION: DAAM2 had a specific value in foretelling the prognosis of LGG, LIHC, and BRCA. High expression level of DAAM2 has longer survival rates in LGG and LIHC. The knockdown of DAAM2 retards the proliferation, invasion, and migration of BRCA cells. This study provides a novel sight of DAAM2 into the exploration of a potential biomarker in pan-cancer.PMID:36790676 | DOI:10.1007/s12094-023-03111-x
Source: Clinical Breast Cancer - February 15, 2023 Category: Cancer & Oncology Authors: Zeying Li Xiao Wei Yichao Zhu Source Type: research
Cancers, Vol. 15, Pages 834: Kynureninase Upregulation Is a Prominent Feature of NFR2-Activated Cancers and Is Associated with Tumor Immunosuppression and Poor Prognosis
Johannes F. Fahrmann
The nuclear factor erythroid 2-related factor 2 (NRF2) pathway is frequently activated in various cancer types. Aberrant activation of NRF2 in cancer is attributed to gain-of-function mutations in the NRF2-encoding gene NFE2L2 or a loss of function of its suppressor, Kelch-like ECH-associated protein 1 (KEAP1). NRF2 activation exerts pro-tumoral effects in part by altering cancer cell metabolism. Previously, we reported a novel mechanism of NRF2 tumoral immune suppression through the selective upregulation of the tryptophan-metabolizing enzyme kynureninase (KYNU) in lung adenocarcinoma. In the cu...
Source: Cancers - January 29, 2023 Category: Cancer & Oncology Authors: Ricardo A. Le ón-Letelier Ali H. Abdel Sater Yihui Chen Soyoung Park Ranran Wu Ehsan Irajizad Jennifer B. Dennison Hiroyuki Katayama Jody V. Vykoukal Samir Hanash Edwin J. Ostrin Johannes F. Fahrmann Tags: Article Source Type: research
The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma
Drug Deliv. 2023 Dec;30(1):1-13. doi: 10.1080/10717544.2022.2152911.ABSTRACTTemozolomide (TMZ) is a conventional chemotherapeutic drug for glioma, however, its clinical application and efficacy is severely restricted by its drug resistance properties. O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme, which can repair the DNA damage caused by TMZ. A large number of clinical data show that reducing the expression of MGMT can enhance the chemotherapeutic efficacy of TMZ. Therefore, in order to improve the resistance of glioma to TMZ, an angiopep-2 (A2) modified nanoprodrug of polytemozolomide (P(TMZ)n) tha...
Source: Drug Delivery - December 29, 2022 Category: Drugs & Pharmacology Authors: Haoyue Xu Yongkang Zhang Linfeng Li Yanhong Ren Feng Qian Lansheng Wang Hongwei Ma Ankang Quan Hongmei Liu Rutong Yu Source Type: research
